Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (7)

Medical Condition

  • Show all (237)
  • Addiction (4)
  • Autoimmune Disorders (15)
    • (-) Lupus (6)
    • Rheumatoid Arthritis (2)
  • Blood Disorders (26)
  • Bone & Muscle (1)
  • Cancer (4)
    • (-) Lymphoma (1)
  • Child Development (1)
  • Developmental Disorders (1)
  • Endocrine & Metabolic Disease (2)
  • Hair and Skin Disorders (2)
  • Healthy Volunteers (8)
  • Heart Disease (1)
  • Liver Disease (1)
  • Lung Disease (2)
  • Meniere's Disease (1)
  • Neurological Disorders (112)
  • Obstetrics & Gynecology (3)
  • Pediatrics (6)
  • Psychiatric Disorders (47)
Displaying 1 - 7 of 7

Study of EBV-Cytotoxic T Lymphocytes (EBV-CTLs) in Patients with Epstein-Barr Virus-Associated Viremia or Malignancies

Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (people who have had a transplant and those who have immune disorders), EBV can cause certain…
Read More

Study of Experimental Gel Drug in Subjects with Persistently Active Systemic Lupus Erythematosus (SLE)

Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
We are studying a medication to see if it is effective in reducing the disease activity of systemic lupus erythematosus (SLE), which is the most common form of lupus. You may qualify for the Achtar study if you have persistently active SLE, are 18 years of age or older, and: Have rash and/or arthritis as part of your SLE symptoms Are currently taking…
Read More

A study for patients with Lupus Nephritis using ACTHAR GEL

Condition: Autoimmune Disorders / Lupus
Investigator: Wooin Ahn, MD
Status: Closed
The purpose of this study is to determine if Acthar gel is a safe and effective therapy for patients with membranous (Class V) lupus nephritis. Class V lupus nephritis is associated with the development of chronic kidney disease and end-stage renal (kidney) disease, and there is no clear therapy for treatment. Currently used therapies arent completely…
Read More

A study for pediatric patients with Systemic Lupus Erythematosus (SLE) using study drug Belimumab

Condition: Autoimmune Disorders / Lupus
Investigator: Lisa Imundo, MD
Status: Closed
The purpose of the study is to find out if study drug belimumab is safe and effective in treating children with active lupus who are also taking other lupus medicine. Belimumab (also known as BENLYSTA hasbeen approved in the United States, Canada, and Europe for the treatment of adults with active SLEwho are receiving other…
Read More

A study on subjects with systemic lupus erythematosus using study drug CC-220

Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
This study is for patients who have been diagnosed with systemic Lupus erythematosus (SLE). SLE is a disease in which the body mistakenly attacks healthy tissue. It can affect the skin, joints, kidneys, brain and other organs. The purpose of this study is to test the effects of an investigational (being tested) study drug, CC 220, in order to find out if CC…
Read More

A study for patients with lupus nephritis using the study drug Obinutuzumab.

Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The purpose of this study is to test the safety and effectiveness of the study drug Obinutuzumab and to find out what effects, good or bad, it may have as an additional therapy in treating your lupus nephritis symptoms.
Read More

A study for patients with lupus using the study drug XmAb5871.

Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The purpose of this clinical trial is to learn about the ability of an experimental treatment XmAb5871 to maintain lupus disease activity improvement achieved by a brief course of disease-suppressing intramuscular (IM) steroid therapy in lupus patients.
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science